Moreover, since PD-L1 has been used in solid tumors as a valid biomarker for a potential response to an immune checkpoint blockade against the PD-1/PD-L1 axis, we realize that its expression per se does not correlate with survival in our glioblastoma cohort of patients. This evidence concerns the gene CD274 and glioblastoma.